A Canadian-based pharmaceutical company has received approval to conduct a clinical study of the psychedelic compound DMT as a treatment for stroke. Under the plan, pharmaceutical development company ...

The Phase 2 study will assess a sub-psychedelic dose of DMT in patients who have suffered an acute ischemic stroke. The biotech is advancing clinical research on DMT for stroke treatment and its ...

The psychedelic drug DMT may be an effective treatment for depression, according to the results of a recently published study. The research also found that the intensity of a person’s psychedelic ...

Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. AGNPF AGN AGW, has completed a feasibility study and has finalized its clinical trial design for a 40 patient phase 2 ...

--Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP ...

Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ:GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients ...

VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an ...

A 2022 report by the Lancet Neurology Commission reveals traumatic brain injury is a global public health concern that affects 55 million people worldwide, according to Neuroscience News. Traumatic ...

DMT could be a more cost-effective treatment for depression, addiction and other conditions. Tripping on DMT usually lasts under one hour, while psychedelic psilocybin lasts up to eight. DMT is the ...

EXTON, Pa., March 12, 2019 /PRNewswire/ -- Expanding adoption of Genentech's Ocrevus among US neurologists has significantly and persistently increased the rate of disease-modifying therapy (DMT) ...

Please provide your email address to receive an email when new articles are posted on . A biotech company based in the U.K. announced that it has initiated a phase 2a study for BPL-003 for ...